Legend Biotech Results Presentation Deck
12
Focused Investments in Pipeline and Development
160
140
120
100
80
60
40
20
0
147
2022 Q3
Operating Expenses ($MM)
-9
R&D delta
7
SG&A delta
145
2023 Q3
This presentation is for investor relations purposes only - Not for product promotional purposes
3Q 2023 OpEx Decreased 1% versus 3Q 2022
The decrease of $8.7 million in R&D expenses was
due to:
Timing of expenses incurred in connection
with the Global Development Plan under the
Janssen Agreement.
The increase of $2.2 million in S&D Expenses was
due to costs associated with the
commercialization of CARVYKTIⓇ.
The increase of $4.9 million in Administrative
Expenses was primarily due to the expansion of
administrative functions to facilitate continuous
business growth and continued investment in
building Legend Biotech's global information
technology infrastructure.
LEGEND
BIOTECHView entire presentation